Tag: Oncology
Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More
AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of ... Read More
Bristol Myers Squibb and 2seventy bio’s Abecma gets positive FDA committee vote for multiple myeloma
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced a favorable vote by ... Read More
FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally recognized oncology company, has received approval from ... Read More
Zephyr AI announces $111m Series A to advance AI in precision medicine
Zephyr AI, Inc., a pioneering healthcare technology company committed to enhancing precision medicine through fast and explainable Artificial Intelligence (AI) solutions, has successfully closed a ... Read More
Eris Lifesciences acquires Biocon Biologics’ branded formulation business for Rs 1,242cr
In a strategic move that reshapes the landscape of India's injectables market, Eris Lifesciences Ltd., a leading player in the branded formulations sector, has announced ... Read More
Zydus introduces cancer treatment IBYRA in India, making advanced therapy accessible
In a groundbreaking development for cancer treatment in India, Zydus Lifesciences has launched Olaparib under the brand name IBYRA, a pioneering PARP inhibitor designed to ... Read More
CureMatch, Spesana forge partnership to revolutionize precision medicine
In a groundbreaking development for the healthcare industry, CureMatch and Spesana have announced a strategic partnership aimed at advancing precision medicine and transforming patient care ... Read More
Immune-Onc Therapeutics gets FDA orphan drug status for IO-202 in CMML
Immune-Onc Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies in immunology and oncology, has achieved a significant milestone with the ... Read More
Kinnate Biopharma agrees to merger with XOMA, boosting shareholder value and advancing cancer research
Kinnate Biopharma Inc. (Nasdaq: KNTE), a leading clinical-stage precision oncology company, has announced a definitive merger agreement with XOMA Corporation, setting the stage for a ... Read More